Table 7. Breast cancer animal models for drug research and development.
| Breast Cancer Typing | Therapy | Drug | Model | References |
| Hormone receptor positive breast cancer (HR+) (ERα+/PR+HER2-) | Antiestrogens | Tamoxifen | CDX model (MCF-7) | Osborne et al., 1985 |
| Fulvestrant | CDX model (MCF-7) | Lee et al., 1995 | ||
| Aromatase inhibitor | Letrozole | CDX model (MCF-7) | Brodie et al., 1998; Wakeling et al., 1991 | |
| Anastrozole | CDX model (MCF-7) | Brodie et al., 1998 | ||
| CDK4 / 6 inhibitor | Palbociclib | CDX model (MDA-MB-435, ZR-75-1) | Fry et al., 2004 | |
| Ribociclib | CDX model (MDA-MB-435) | Vora et al., 2014 | ||
| Abemaciclib | CDX model (MDA-MB-231) | Knudsen et al., 2017 | ||
| HER2-positive breast cancer (ERα-PR-HER2+) | Monoclonal antibodies | Trastuzumab | CDX model (BT474) | Baselga et al., 1998 |
| Epidermal growth factor tyrosine kinase inhibitor | Lapatinib | CDX model (BT474) | Rusnak et al., 2001 | |
| Triple negative breast cancer (ERα-PR-HER2-) | Chemotherapy drugs | Cisplatin | GEMM (Brca1 mutant breast cancer mice) | Shafee et al., 2008 |
| ADP ribose polymerase (PARP) inhibitors | Olaparib | GEMM (BRCA1Co/Co - MMTV-Cre-p53+/− mice) | To et al., 2014 | |
| PD-L1 positive patients | Immune checkpoint inhibitor | Pembrolizumab | Hu-PDX model | Wang et al., 2018 |